Medical
Distalmotion raised $150 million, led by Revival Healthcare Capital, to grow US sales. In January 2026 Johnson & Johnson's venture arm also invested an undisclosed amount.
A dated step forward on the record · Company-reported
What the source says
“Revival Healthcare Capital led the financing, which also included inside investor participation.”
What it means
Dexter, from Distalmotion, is at stage 5 of 5 on our ladder: regulator-cleared or mass market. Its stage is set by other milestones on its record; this one adds to the history. This line rests on the company's own announcement; no regulator, customer or independent report confirms it in our sources yet.
Human help: Our sources report it working without human help.
More on Dexter
- The FDA cleared Dexter for more gynecology operations, including pelvic-organ prolapse repair and endometriosis surgery: its fourth US clearance.
- The FDA cleared Dexter for hysterectomy (removal of the womb) through the 510(k) route.
- AdventHealth, which runs 50 hospitals in nine states, bought several Dexter robots: the company's first multi-robot sale in the US.
- The FDA cleared Dexter for gallbladder removal through the 510(k) route.
- Surgeons at UC San Diego Health did the first two US outpatient operations with Dexter, both hernia repairs.
- The FDA cleared Dexter through the De Novo route (DEN230084) for groin (inguinal) hernia repair in adults. More than 1,300 patients had already been treated with it in Europe.